Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccine and Inactivated Influenza Vaccine (IIV) in Pregnant Women
NCT06503900Phase 4Completed
- Sponsor
- Duke University
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mRNA COVID-19 vaccine and influenza virus quadrivalent inactivated vaccine in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Duke University. Primary endpoint: Number of Participants With an Adverse Birth Outcome. Started Sep 2024; status: completed.
02
Drugs
mRNA COVID-19 vaccineinfluenza virus quadrivalent inactivated vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06503900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503900.